{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:04:55Z","timestamp":1777500295615,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Outcomes for patients with myeloid blast phase chronic myeloid leukemia (CML-MBP) are dismal, and no preferred chemotherapy regimen has been identified. Recent studies have suggested a higher response rate with administration of timed-sequenced regimens (TSR) (purine analog, high-dose cytarabine, anthracycline) in high-risk acute myeloid leukemia patients. We retrospectively evaluated outcomes of newly diagnosed CML-MBP patients consecutively treated at our institution with a TSR or standard-dose cytarabine and an anthracycline (\u201c7\u2009+\u20093\u201d) combined with a tyrosine-kinase inhibitor (TKI) between 2011 and 2023. Endpoints of interest included hematologic response, clinically significant cytogenetic response (CSCR) defined as achieving at least a minor cytogenetic response (Ph\u2009+\u2009metaphases 0%-\u226465%) after induction therapy, event-free survival (EFS), and overall survival (OS). A total of 18 patients with CML-MBP were included of whom 9 (50%) received a TSR and 9 (50%) received \u201c7\u2009+\u20093\u201d. Hematologic response (55.6% vs. 55.6%) and CSCR (25% vs. 37.5%) were similar between TSR- and \u201c7\u2009+\u20093\u201d treated patients. Twelve patients (66.7%) experienced at least one grade\u2009\u2265\u20093 non-hematologic, end-organ toxicity with 33.3% and 11.1% of TSR- and 7\u2009+\u20093-treated patients, respectively, experiencing at least two. Our data suggests that intensification of upfront chemotherapy does not appear to improve treatment outcomes in CML-MBP patients however, further studies are warranted to confirm these findings involving a larger cohort.<\/jats:p>","DOI":"10.1007\/s00277-024-06045-8","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T01:02:12Z","timestamp":1729645332000},"page":"5395-5403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1678-1345","authenticated-orcid":false,"given":"Benjamin J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-2490","authenticated-orcid":false,"given":"Shawn P.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2737-5243","authenticated-orcid":false,"given":"Jean","family":"Doh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8597-3271","authenticated-orcid":false,"given":"Stefan O.","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8822-1814","authenticated-orcid":false,"given":"Deepa","family":"Jeyakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-7645","authenticated-orcid":false,"given":"Piyanuch","family":"Kongtim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5511-6153","authenticated-orcid":false,"given":"Kiran","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"6045_CR1","unstructured":"National Comprehensive Cancer Network Guidelines (2023) http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed September 10, 2023"},{"key":"6045_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/10428190601075973","volume":"48","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Garcia-Manero G et al (2007) A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 48:283\u2013289","journal-title":"Leuk Lymphoma"},{"key":"6045_CR3","doi-asserted-by":"crossref","unstructured":"Deau B, Nicolini FE, Guilhot J (2011) The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leuk Res 35:777\u2013782.","DOI":"10.1016\/j.leukres.2010.11.004"},{"key":"6045_CR4","doi-asserted-by":"crossref","unstructured":"Minetto P, Candoni A, Guolo F et al (2020) Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. Cancers (Basel) 13:34","DOI":"10.3390\/cancers13010034"},{"key":"6045_CR5","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/ajh.27054","volume":"98","author":"TM Kadia","year":"2023","unstructured":"Kadia TM, Ravandi F, Molica M et al (2023) Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol 98:1711\u20131720","journal-title":"Am J Hematol"},{"key":"6045_CR6","doi-asserted-by":"publisher","first-page":"106318","DOI":"10.1016\/j.leukres.2020.106318","volume":"93","author":"MM Solh","year":"2020","unstructured":"Solh MM, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A (2020) Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+\/-Idarubicin versus 3\u2009+\u20097 (anthracycline\u2009+\u2009cytarabine). Leuk Res 93:106318","journal-title":"Leuk Res"},{"key":"6045_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-021-01106-1","volume":"14","author":"K Saxena","year":"2021","unstructured":"Saxena K, Jabbour E, Issa G et al (2021) Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol 14:94","journal-title":"J Hematol Oncol"},{"key":"6045_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447","journal-title":"Blood"},{"key":"6045_CR9","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/cncr.30864","volume":"123","author":"P Jain","year":"2017","unstructured":"Jain P, Kantarjian HM, Ghorab A et al (2017) Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer 123:4391\u20134402","journal-title":"Cancer"},{"key":"6045_CR10","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/S2352-3026(21)00370-7","volume":"9","author":"M Copland","year":"2022","unstructured":"Copland M, Slade D, McIlroy G et al (2022) Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1\/2 trial. Lancet Haematol 9:e121\u2013e132","journal-title":"Lancet Haematol"},{"key":"6045_CR11","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/ajh.25939","volume":"95","author":"Y Abaza","year":"2020","unstructured":"Abaza Y, Kantarjian H, Alwash Y et al (2020) Phase I\/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol 95:1288\u20131295","journal-title":"Am J Hematol"},{"key":"6045_CR12","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1080\/10428194.2017.1397666","volume":"59","author":"M Ruggiu","year":"2018","unstructured":"Ruggiu M, Oberkampf F, Ghez D et al (2018) Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia. Leuk Lymphoma 59:1659\u20131665","journal-title":"Leuk Lymphoma"},{"key":"6045_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1159\/000506346","volume":"143","author":"A Maiti","year":"2020","unstructured":"Maiti A, Franquiz MJ, Ravandi F et al (2020) Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with Philadelphia chromosome-positive Advanced Myeloid Leukemias. Acta Haematol 143:567\u2013573","journal-title":"Acta Haematol"},{"key":"6045_CR14","doi-asserted-by":"crossref","unstructured":"Senapati J, Ravandi F, Dinardo CD et al (2023) A phase 2 study of the combination of decitabine (DAC), venetoclax (VEN), and ponatinib in patients (pts) with chronic myeloid leukemia (CML) in accelerated phase (AP)\/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph+) acute myeloid leukemia (AML). J Clin Oncol 41:(16s_suppl;abstr e19044)","DOI":"10.1200\/JCO.2023.41.16_suppl.e19044"},{"key":"6045_CR15","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/cncr.22535","volume":"109","author":"S Fruehauf","year":"2007","unstructured":"Fruehauf S, Topaly J, Buss EC et al (2007) Imatinib combined with mitoxantrone\/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer 109:1543\u20131549","journal-title":"Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06045-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06045-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06045-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:11:15Z","timestamp":1735866675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06045-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6045"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06045-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"8 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the University of California Irvine Institutional Review Board (IRB# 3397) and a waiver of informed consent was granted. All study procedures were conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and Good Clinical Practice standards by the University of California Irvine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}